198
Views
1
CrossRef citations to date
0
Altmetric
Perspective

Monoclonal Antibody Dose Determination and Biodistribution Into Solid Tumors

, &
Pages 333-344 | Published online: 09 Mar 2011
 

Abstract

Monoclonal antibodies are increasingly being used as protein therapeutics for cancer. They offer very specific binding to target molecules on the surface of cancer cells, relatively few side effects and predictable pharmacokinetics. Tumor shrinkage is seen in some patients, and an incremental improvement in survival occurs in the group. However, due to their large size and consequent slow diffusion, antibody penetration deep into tumors may be inhomogeneous. Even if only a few cells, deep in tumors, escape therapy, they can regrow and lead to clinical relapse, limiting the significant potential of monoclonal antibody therapy. This leads to questions about optimal dosing for monoclonal antibodies. Methods to determine monoclonal antibody dose include maximum-tolerated dose studies, pharmacokinetically and pharmacodynamically guided dosing, randomized dose-ranging studies, imaging of antibody biodistribution and competitive-binding studies. Limitations of these methods, and future directions to possibly overcome these limitations will be discussed.

Acknowledgements

The authors wish to thank Paula Ehrlich and Ray Gibson for their contributions to early discussions of the enhanced competition experiment.

Financial & competing interests disclosure

Robert A Beckman is an employee of and stockholder in Daiichi Sankyo Pharmaceutical Development, and a stockholder in Johnson & Johnson and Merck & Co., Inc. Reinhard von Roemeling is an employee of and stockholder in Daiichi Sankyo Pharmaceutical Development. Andrew M Scott is an employee of the Ludwig Institute for Cancer Research, and a consultant to Life Sciences Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.